The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
Open accessAbstract
BACKGROUND: The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. METHODS: We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). RESULTS: The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. CONCLUSIONS: Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early weight loss medications, such as fenfluramine (Fen-Phen) and sibutramine, were withdrawn due to severe cardiovascular and psychiatric side effects [3,4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite 5–10% weight loss in trials, it was discontinued in 2010 after the SCOUT trial showed elevated cardiovascular events (e.g., stroke) in high-risk patients [4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the concept of treating obesity to reduce the risk of cardiovascular complications has been hampered by the lack of evidence from trials indicating that lifestyle or pharmacologic interventions for overweight or obesity improve cardiovascular outcomes. 11-15”
From Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023) · cites this paper as [13]
In the citing paper
“Prospective studies that evaluated the effect of nonsurgical weight loss interventions on CV event reduction have been disappointing [4, 5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [5]
In the citing paper
“Specifically, across the obesity CVOTs, SELECT is the only study to our knowledge that only enrolled participants with established CVD, whereas in the other obesity CVOTs, 24.9% to 50.5% of participants had no prior events [5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Long-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572
S UCCESSFUL W EIGHT L OSS M AINTENANCE
Wing, R. R., & Hill, J. O. (2001) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.21.1.323 · Cited by 1,382
Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis
Dattilo, A., & Kris-Etherton, P. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/56.2.320 · Cited by 1,055
Secular Trends in Cardiovascular Disease Risk Factors According to Body Mass Index in US Adults
Gregg, E. W. (2005) · JAMA · doi:10.1001/jama.293.15.1868 · Cited by 959
Blood Pressure Lowering Treatment Trialists’ Collaboration (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1410 · Cited by 789
Flagged first, then by citations
Research works printed but not linked: 3
- 1996, Can J Cardiol, 12, 127
- 1994, Lancet, 344, 1383
- Lyznicki JM, 2001, Am Fam Physician, 63, 2185
Cited by
Sorted by citations
Items 201–300 of 943
Derosa, G., Cicero, A. F. G., D’Angelo, A., Fogari, E., & Maffioli, P. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2011.01280.x · Cited by 53
Pharmacological and non-pharmacological interventions to influence adipose tissue function
Westerink, J., & Visseren, F. L. J. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-13 · Cited by 54
A comparative study of five centrally acting drugs on the pharmacological treatment of obesity
Suplicy, H. L., Boguszewski, C. L., dos Santos, C. M. C., de Figueiredo, M. D. D., da Cunha, D. R., & Radominski, R. B. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.225 · Cited by 56
Management of Obesity in the National Health and Nutrition Examination Survey (NHANES), 2007–2008
Samaranayake, N. R., Ong, K. L., Leung, R. Y. H., & Cheung, B. M. Y. (2012) · Annals of Epidemiology · doi:10.1016/j.annepidem.2012.01.001 · Cited by 52
de Luis, D. A., Domingo, J. C., Izaola, O., Casanueva, F. F., Bellido, D., & Sajoux, I. (2016) · Endocrine · doi:10.1007/s12020-016-0964-z · Cited by 55
Lenon, G. B., Li, K. X., Chang, Y., Yang, A. W. H., Costa, C. D., Li, C. G., Cohen, M. M., Mann, N. J., & Xue, C. C. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/435702 · Cited by 52
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths
Scirica, B. M., Lincoff, A. M., Lingvay, I., Bogdanski, P., Buscemi, S., Colhoun, H., Craciun, A.-E., Ezhov, M., Hardt-Lindberg, S., Kleist Jeppesen, O., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.007 · Cited by 51
Brown adipose tissue and regulation of human body weight
Harb, E., Kheder, O., Poopalasingam, G., Rashid, R., Srinivasan, A., & Izzi‐Engbeaya, C. N. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3594 · Cited by 53
Maintenance of Weight Loss in Adolescents: Current Status and Future Directions
Butryn, M. L., Wadden, T. A., Rukstalis, M. R., Bishop‐Gilyard, C. T., Xanthopoulos, M. S., Louden, D. M., & Berkowitz, R. I. (2010) · Journal of Obesity · doi:10.1155/2010/789280 · Cited by 53
Treatment of lipid disorders in obesity
Tonstad, S., & Després, J. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.83 · Cited by 52
Enkhmaa, B., Surampudi, P. N., Anuurad, E., & Berglund, L. (2015) · Europe PMC (PubMed Central) · Cited by 50
Long-term effects of weight-reducing drugs in hypertensive patients
Siebenhofer, A., Jeitler, K., Horvath, K., Berghold, A., Siering, U., & Semlitsch, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub3 · Cited by 51
The toxicity of lithium to human cardiomyocytes
Shen, J., Li, X., Shi, X., Wang, W., Zhou, H., Wu, J., Wang, X., & Li, J. (2020) · Environmental Sciences Europe · doi:10.1186/s12302-020-00333-6 · Cited by 50
Role of serotonin in body weight, insulin secretion and glycaemic control
Georgescu, T. R., Lyons, D. J., & Heisler, L. K. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.12960 · Cited by 51
Smith, S. R., O'Neil, P. M., Astrup, A. V., Finer, N., Sanchez‐Kam, M., Fraher, K., Fain, R., & Shanahan, W. R. (2014) · Obesity · doi:10.1002/oby.20841 · Cited by 50
Self-citationSafety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications
Halpern, B., & Halpern, A. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.994502 · Cited by 51
Browning effects of (-)-epicatechin on adipocytes and white adipose tissue
Varela, C. E., Rodríguez, A., Romero‐Valdovinos, M., Mendoza‐Lorenzo, P., Mansour, C. M., Ceballos, G. M., Villarreal, F. J., & Ramírez‐Sánchez, I. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.051 · Cited by 52
Effects of Caffeine on Brown Adipose Tissue Thermogenesis and Metabolic Homeostasis: A Review
Schaik, L. V., Kettle, C., Green, R., Irving, H. R., & Rathner, J. A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.621356 · Cited by 50
Chew, N., Ng, C. H., Muthiah, M. D., & Sanyal, A. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01027-5 · Cited by 49
The use of serotonergic drugs to treat obesity – is there any hope?
Bello, N. T., & Liang, N.-C. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s11859 · Cited by 49
Metabolic actions of hypothalamic SIRT1
Coppari, R. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.01.002 · Cited by 47
Gray, L. J., Cooper, N. J., Dunkley, A. J., Warren, F. C., Ara, R., Abrams, K. R., Davies, M. J., Khunti, K. K., & Sutton, A. J. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00981.x · Cited by 47
The safety of pharmacologic treatment for pediatric obesity
Chao, A. M., Wadden, T. A., & Berkowitz, R. I. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1437143 · Cited by 49
Savarese, G., Schiattarella, G. G., Lindberg, F., Anker, M. S., Bayés‐Genís, A., Bäck, M., Braunschweig, F., Bucciarelli‐Ducci, C., Butler, J., Cannata, A. N., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3676 · Cited by 52
Pharmacogenetics of Drugs Withdrawn from the Market
Zhang, W., Roederer, M. W., Chen, W., Fan, L., & Zhou, H.-H. (2012) · Pharmacogenomics · doi:10.2217/pgs.11.137 · Cited by 46
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
Gersh, B. J. (2011) · Yearbook of Cardiology · doi:10.1016/j.ycar.2010.12.010 · Cited by 46
Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice
Gadde, K. M., & Raj, Y. P. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0859-2 · Cited by 49
Pharmacotherapy for obesity: What you need to know
Bersoux, S., Byun, T. H., Chaliki, S. S., & Poole, K. G. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84a.16094 · Cited by 49
Fox, K. M., Bousser, M., Amarenco, P., Chamorro, Á., Fisher, M., Ford, I., Hennerici, M. G., Mattle, H. P., & Rothwell, P. M. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.04.206 · Cited by 45
Koncz, D., Tóth, B., Roza, O., & Csupor, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.611361 · Cited by 46
Neuroendocrine adaptations to bariatric surgery
Dixon, J. B., Lambert, É., & Lambert, G. W. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.05.033 · Cited by 45
Hayes, J., Bhaskaran, K., Batterham, R. L., Smeeth, L. L., & Douglas, I. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.86 · Cited by 44
Lam, C. S. P., Rodríguez, Á., Aminian, A., Ferrannini, E., Heerspink, H. J. L., Jastreboff, A. M., Laffin, L. J., Pandey, A., Ray, K. K., Ridker, P. M., et al. (2025) · Obesity · doi:10.1002/oby.24332 · Cited by 51
Review of Treatment Options for Nonalcoholic Fatty Liver Disease
Corrado, R., Torres, D. M., & Harrison, S. A. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2013.09.001 · Cited by 44
Management of Hypothalamic Obesity.
Müller, H. (2020) · Endocrinology and metabolism clinics of North America (Print) · doi:10.1016/j.ecl.2020.05.009 · Cited by 32
Sibutramine — Another Flawed Diet Pill
Curfman, G., Morrissey, S., & Drazen, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejme1007993 · Cited by 44
Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity
Huynh, K., Klose, M., Krogsgaard, K., Drejer, J., Byberg, S., Madsbad, S., Magkos, F., Aharaz, A., Edsberg, B., Tfelt-Hansen, J., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-0972 · Cited by 43
Assessment and management of obesity in childhood and adolescence
Baur, L. A., Hazelton, B. J., & Shrewsbury, V. A. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.165 · Cited by 42
Do we need anti‐obesity drugs?
Hainer, V., & Hainerová, I. A. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2349 · Cited by 45
MANAGEMENT OF ENDOCRINE DISEASE: Childhood-onset craniopharyngioma: state of the art of care in 2018
Muller, H. L. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-1021 · Cited by 43
Saichanapan, J., Promsuwan, K., & Limbut, W. (2020) · Talanta · doi:10.1016/j.talanta.2020.120788 · Cited by 43
Acquired hypothalamic obesity: A clinical overview and update
Roth, C. L., & McCormack, S. E. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15530 · Cited by 42
Melanocortin‐4 receptor complexity in energy homeostasis,obesity and drug development strategies
Fatima, M. T., Ahmed, I., Fakhro, K. A., & Akil, A. A. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14618 · Cited by 45
Pharmacotherapy for the treatment of obesity
Sweeting, A., HOCKING, S. L., & Markovic, T. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.005 · Cited by 45
Phentermine/Topiramate extended-release capsules (qsymia) for weight loss.
Lonneman, D. J., Rey, J. A., & McKee, B. (2013) · Europe PMC (PubMed Central) · Cited by 42
Lorcaserin: An investigational serotonin 2C agonist for weight loss
Hurren, K. M., & Berlie, H. D. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100638 · Cited by 43
Obesity and diabetes mellitus in the Arab world
Alzaman, N. S., & Ali, A. (2016) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2016.03.009 · Cited by 43
Halpern, B., & Mancini, M. C. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1247807 · Cited by 42
Psychological Co-morbidities of Physical Illness
Pagoto, S. (2011) · Springer eBooks · doi:10.1007/978-1-4419-0029-6 · Cited by 44
An overview of national clinical guidelines for the management of childhood obesity in primary care
Richardson, L., Paulis, W. D., van Middelkoop, M., & Koes, B. W. (2013) · Preventive Medicine · doi:10.1016/j.ypmed.2013.08.010 · Cited by 41
Cohen, P. A., Benner, C. S., & McCormick, D. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1828-0 · Cited by 41
Laparoscopic Adjustable Gastric Banding and Other Devices for the Management of Obesity
Dixon, J. B., Straznicky, N. E., Lambert, É., Schlaich, M. P., & Lambert, G. W. (2012) · Circulation · doi:10.1161/circulationaha.111.040139 · Cited by 41
Tigliane Diterpenoids as a New Type of Antiadipogenic Agents Inhibit GRα-Dexras1 Axis in Adipocytes
Song, Q., Rao, Y., Tang, G., Sun, Z., Zhang, J.-S., Huang, Z., & Yin, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01693 · Cited by 41
Alsaqaaby, M. S., Cooney, S., le Roux, C. W., & Pournaras, D. J. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00098-6 · Cited by 42
Metformin-based treatment for obesity-related hypertension
He, H., Zhao, Z., Chen, J., Ni, Y., Zhong, J., Yan, Z., Li, Y., Liu, D., Pletcher, M. J., & Zhu, Z. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e328353e249 · Cited by 40
Joo, J. K., & Lee, K. S. (2014) · Journal of Menopausal Medicine · doi:10.6118/jmm.2014.20.3.90 · Cited by 41
Weight Considerations in Pharmacotherapy for Type 2 Diabetes
Cheng, V., & Kashyap, S. R. (2010) · Journal of Obesity · doi:10.1155/2011/984245 · Cited by 40
Ullah, M. I., & Tamanna, S. (2025) · Medicines · doi:10.3390/medicines12030019 · Cited by 38
“Despite 5–10% weight loss in trials, it was discontinued in 2010 after the SCOUT trial showed elevated cardiovascular events (e.g., stroke) in high-risk patients [4].”
Combination phentermine and topiramate extended release in the management of obesity.
Alfaris, N., Minnick, A. M., Hopkins, C. M., Berkowitz, R. I., & Wadden, T. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1041505 · Cited by 38
Why do we need drugs to treat the patient with obesity?
Bray, G. A. (2013) · Obesity · doi:10.1002/oby.20394 · Cited by 40
Cardiovascular safety and diabetes drug development
Drucker, D. J., & Goldfine, A. B. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62299-4 · Cited by 38
Mutations in Melanocortin-3 Receptor Gene and Human Obesity
Yang, Z., & Tao, Y. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.01.002 · Cited by 40
Murtaza, M., Khan, G., Aftab, M. F., Afridi, S. K., Ghaffar, S., Ahmed, A., Hafizur, R. M., & Waraich, R. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178910 · Cited by 38
Polymeric Carriers for Controlled Drug Delivery in Obesity Treatment
Huang, D., Deng, M., & Kuang, S. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.09.004 · Cited by 38
Sumińska, M., Podgórski, R., Bogusz‐Górna, K., Skowrońska, B., Mazur, A., & Fichna, M. (2022) · Obesity Reviews · doi:10.1111/obr.13440 · Cited by 39
Dedov, I. I., Melnichenko, G. A., Troshina, E. A., Mazurina, N. V., & Galieva, M. O. (2018) · Obesity Facts · doi:10.1159/000488880 · Cited by 39
Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases
Nguyễn, T. T. B., Jin, Y., & Chung, H. (2017) · Molecules · doi:10.3390/molecules22101795 · Cited by 39
Shu, Q., Chen, L., Wu, S., Li, J., Liu, J., Xiao, L., Chen, R., & Liang, F.-X. (2020) · Obesity Facts · doi:10.1159/000503752 · Cited by 39
Bredella, M. A., Gerweck, A. V., Barber, L. A., Breggia, A., Rosen, C. J., Torriani, M., & Miller, K. K. (2014) · Bone · doi:10.1016/j.bone.2014.01.022 · Cited by 36
Combination therapy for obesity
Wilding, J. P. H. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117737401 · Cited by 37
Bowels control brain: gut hormones and obesity
Bewick, G. A. (2012) · Biochemia Medica · doi:10.11613/bm.2012.032 · Cited by 36
Mukherjee, J., Baranwal, A., & Schade, K. N. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666160517115450 · Cited by 37
Safety and tolerability review of lorcaserin in clinical trials
Greenway, F. L., Shanahan, W. R., Fain, R., Ma, T., & Rubino, D. (2016) · Clinical Obesity · doi:10.1111/cob.12159 · Cited by 36
Scientific rigor and credibility in the nutrition research landscape
Kroeger, C. M., Garza, C., Lynch, C. J., Myers, E. F., Rowe, S. B., Schneeman, B. O., Sharma, A. M., & Allison, D. B. (2018) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqx067 · Cited by 41
Self-citationBenefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
Sandsdal, R. M., Juhl, C. R., & Torekov, S. S. (2019) · Drug Safety · doi:10.1007/s40264-019-00812-7 · Cited by 37
Modern Obesity Pharmacotherapy: Weighing Cardiovascular Risk and Benefit
Cunningham, J. W., & Wiviott, S. D. (2014) · Clinical Cardiology · doi:10.1002/clc.22304 · Cited by 35
Naltrexone/Bupropion: An Investigational Combination for Weight Loss and Maintenance
Makowski, C. T., Gwinn, K. M., & Hurren, K. M. (2011) · Obesity Facts · doi:10.1159/000335352 · Cited by 37
Garvey, W. T. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.806481 · Cited by 37
Nilsson, P. M., Korduner, J., & Magnusson, M. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-1027-7 · Cited by 35
Rooney, J. S., McDowell, A., Strachan, C. J., & Gordon, K. C. (2015) · Talanta · doi:10.1016/j.talanta.2015.02.016 · Cited by 35
Jørgensen, M. E., Torp-Pedersen, C. T., Finer, N., Caterson, I. D., James, W. P. T., Legler, U. F., & Andersson, C. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.12.009 · Cited by 34
Self-citationBarrea, L., Pugliese, G., Muscogiuri, G., Laudisio, D., Colao, A. A. L., & Savastano, S. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.20.03179-x · Cited by 35
Meyers, K. R., López, M., Ho, J., Wills, S., Rayalam, S., & Taval, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-71249-7 · Cited by 34
Jordan, J., Nilsson, P. M., Kotsis, V., Olsen, M. H., Grassi, G. M., Yumuk, V., Hauner, H., Zahorska‐Markiewicz, B., Toplak, H., Engeli, S., et al. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000473 · Cited by 34
Self-citationHauner, H., Hastreiter, L., Werdier, D., Chen-Stute, A., Scholze, J., & Blüher, M. (2017) · Obesity Facts · doi:10.1159/000478098 · Cited by 34
Liraglutide in Weight Management
Pi-Sunyer, X. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1509759 · Cited by 34
Khaity, A. M., Al-dardery, N. M., Albakri, K. A., Abdelwahab, O. A., Hefnawy, M. T., Yousef, Y. S. A. H., Taha, R. E. W., Swed, S., Hafez, W., Hurlemann, R., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1153648 · Cited by 35
Obstructive sleep apnoea in obesity: A review
Tai, J. E., Phillips, C. L., Yee, B. J., & Grunstein, R. R. (2024) · Clinical Obesity · doi:10.1111/cob.12651 · Cited by 43
Recent advances in the pathophysiology and pharmacological treatment of obesity
Chugh, P. K., & Sharma, S. (2012) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2012.01347.x · Cited by 33
Weight loss and coronary heart disease
Danaei, G., Robins, J. M., Hu, F. B., Manson, J. E., & Hernán, M. Á. (2015) · Epidemiology · doi:10.1097/ede.0000000000000428 · Cited by 34
α-Cedrene protects rodents from high-fat diet-induced adiposity via adenylyl cyclase 3
Tong, T., Yu, R., & Park, T. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0176-0 · Cited by 34
CNS-targeting pharmacological interventions for the metabolic syndrome
Stemmer, K., Müller, T. D., DiMarchi, R. D., Pfluger, P. T., & Tschöp, M. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129195 · Cited by 33
Evaluation and Management of Early Onset Genetic Obesity in Childhood
Malhotra, S., Sivasubramanian, R., & Srivastava, G. (2021) · Journal of Pediatric Genetics · doi:10.1055/s-0041-1731035 · Cited by 37
Packer, M., Zile, M. R., Kramer, C. M., DiMaria, J. M., Baum, S. J., Litwin, S. E., Murakami, M., Zhou, C., Ou, Y., Koeneman, L., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.06.058 · Cited by 34
Bucerius, J. A., Vijgen, G. H. E. J., Brans, B. T., Bouvy, N. D., Bauwens, M., Rudd, J. H. F., Havekes, B., Fayad, Z. A., Lichtenbelt, W. D. V. M., & Mottaghy, F. M. (2015) · Medicine · doi:10.1097/md.0000000000000725 · Cited by 32
Pharmacotherapy of Obesity: Limits and Perspectives
Rosa-Gonçalves, P., & Majerowicz, D. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00328-6 · Cited by 33
Obesity an overview: Genetic conditions and recent developments in therapeutic interventions
Rao, V., Candasamy, M., & Bhattamisra, S. K. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.05.004 · Cited by 33
Lee, H.-G., Lu, Y., Je, J.-G., Jayawardena, T. U., Kang, M., Lee, S., Kim, T.-H., Lee, D.-S., Lee, J., Yim, M., et al. (2021) · Marine Drugs · doi:10.3390/md19020091 · Cited by 32
Predictors of Congestive Heart Failure after Treatment with an Endothelin Receptor Antagonist
Hoekman, J., Heerspink, H. J. L., Viberti, G. C., Green, D., Mann, J. F. E., & de Zeeuw, D. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07040713 · Cited by 32
Derosa, G., Maffioli, P., & Sahebkar, A. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12874 · Cited by 32
Metadata
- Authors
- James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., & Renz, C. L.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- The University of Sydney (AU)
- Pontifícia Universidade Católica do Rio de Janeiro (BR)
- University College London (GB)
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- Gentofte Hospital (DK)
- University of Alberta (CA)
- Abbott (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-02
- Volume
- 363
- Issue
- 10
- Pages
- 905-917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2119779723
- Cited by
- 943
- References
- 33
- Citations by year
- 2026: 27 · 2025: 43 · 2024: 50 · 2023: 40 · 2022: 35 · 2021: 50 · 2020: 45 · 2019: 36 · 2018: 54 · 2017: 38 · 2016: 63 · 2015: 69 · 2014: 75 · 2013: 91 · 2012: 93
- FWCI
- 75.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- UCrea (University of Cantabria) (submittedVersion, cc-by)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- ORBi (University of Liège) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- University of Cambridge
- Eisai
- Novo Nordisk
- Shionogi
- Servier
- Allergan
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- sibutramine, cardiovascular outcomes, obesity, overweight, weight management, cardiovascular risk, myocardial infarction, stroke, cardiovascular mortality, type 2 diabetes, blood pressure, weight loss, older adults, drug safety, appetite suppressants, anti-obesity drugs, cardiovascular events, cardiovascular risk reduction, cardiovascular risk stratification
- MeSH terms
- Aged, Appetite Depressants, Blood Pressure, Cardiovascular Diseases, Cyclobutanes, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction, Obesity, Stroke, Overweight, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
